A slew of recent user fee date extensions for oral JAK1-inhibitors has prompted speculation that the US Food and Drug Administration might convene an advisory committee to vet safety concerns with the class.
Although product sponsors are not providing much in the way of details, the recent goal date extensions come in the wake of results from a long-term, postmarketing safety study that showed cardiovascular and malignancy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?